UB
NTLA icon

UMB Bank’s Intellia Therapeutics NTLA Stock Holding History

UMB Bank’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$2.25K – 2337
2025
Q4 		$2.25K Buy
+250
New +$3.44K ﹤0.01% 2163
2022
Q3 		– Sell
-79
Closed -$4K – 1903
2022
Q2 		$4K Hold
79
– – ﹤0.01% 1629
2022
Q1 		$6K Hold
79
– – ﹤0.01% 1627
2021
Q4 		$9K Buy
+79
New +$9.9K ﹤0.01% 1480

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UMB Bank's NTLA Position: Q1 2026 in Review

UMB Bank sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 250 shares — an estimated $2.25K sold.

UMB Bank first reported a position in NTLA in Q4 2021 and held it in 4 quarters. The position peaked at $9K in Q4 2021. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • UMB Bank reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • UMB Bank sold 250 Intellia Therapeutics shares in Q1 2026, an estimated $2.25K.
  • UMB Bank first reported a position in Intellia Therapeutics in Q4 2021 and held it in 4 quarters.
  • UMB Bank's Intellia Therapeutics position peaked at $9K in Q4 2021.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on UMB Bank's 13F filing for Q1 2026, filed 11 May 2026.